Glyco-Immune Diagnostic Signatures and Therapeutic Targets of Mesothelioma
Annual rept. 15 Jun 2012-14 Jun 2013
NEW YORK UNIV MEDICAL CENTER NY
Pagination or Media Count:
This project is funded in order to investigate immunoprofiles of serum anti-glycan antibodies recognizing Mesothelioma-derived aberrant glycans in human subjects and in animal models of Mesothelioma. This is accomplished using a one of a kind printed glycan array which has been developed by us at the New York University School of Medicine NYU SoM and has now been expanded by addition of 177 novel glycan probes, many of which are Mesothelioma-specific. It is expected that the results of these experiments will allow us to diagnose and prognosticate Mesothelioma earlier during its development. Results of our experiments using rat model of human Mesothelioma should also provide leads into the immuno-preventive and immunotherapeutic approaches to treatments of the military personnel of high-risk for this malignancy due to their potential long-term exposure to carcinogenic form of asbestos during their service.
- Medicine and Medical Research